Patrick Landazuri

Dr. Patrick Landazuri

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Epilepsy Research
Verified
Journal Article
Open access
PLPatrick Landazuri
Patrick Landazuri
JSJerry Shih
Jerry Shih
ELEric Leuthardt
Eric Leuthardt
SBSharona Ben-Haim
Sharona Ben-Haim
JNJoseph Neimat
Joseph Neimat
JBJames Baumgartner
James Baumgartner
To report one-year seizure outcomes, procedural data, and quality of life scores following laser interstitial thermal therapy (LITT) of epileptogenic foci. Data from an ongoing prospective, multi-center registry were assessed. Procedural information, Engel seizure outcomes, and quality of life (QoL) scores were analyzed. A responder analysis was performed to better understand potential clinical characteristics that could influence seizure outcome. Sixty patients have been enrolled into LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System) specifically for epilepsy treatment, of which 42 reached one year follow up. Engel I outcome was achieved in 64.3 % at one year follow up. Patients with mesial temporal lobe epilepsy (MTLE) comprised 56.7 % of this cohort of multiple epilepsy types. Other significant etiologies included focal cortical dysplasia, hypothalamic hamartoma, cavernoma, heterotopias, and tuberous sclerosis. Median length of stay was 32.7 h. At discharge, head pain score averaged 1.4 ± 2.1 on a scale from 1 to 10. Five adverse events were reported, one categorized as serious. Seizure worry and social functioning scores improved significantly in quality of life measures. Surgical treatment with LITT for epileptic foci is a safe and effective treatment option for people with drug resistant epilepsy. Our multicenter prospective seizure outcomes continue to expand published LITT experience in MTLE as well as non-MTLE epilepsies. The minimally invasive nature allows for short hospitalizations with minimal reported pain and discomfort.

13 August 2021 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
CMChristopher Miller
Christopher Miller
BSBryan Schatmeyer
Bryan Schatmeyer
PLPatrick Landazuri
Patrick Landazuri
UUUtku Uysal
Utku Uysal
JNJules Nazzaro
Jules Nazzaro
JCJennifer J. Cheng
Jennifer J. Cheng
Objective: Stereoelectroencephalography (sEEG) is an intracranial encephalography method of expanding use. The need for increased epilepsy surgery access has led to the consideration of sEEG adoption by new or expanding surgical epilepsy programs. Data regarding safety and efficacy are uncommon outside of high‐volume, well‐established centers, which may be less applicable to newer or low‐volume centers. The objective of this study was to add to the sEEG outcomes in the literature from the perspective of a rapidly expanding center.Methods: A retrospective chart review of consecutive sEEG cases from January 2016 to December 2019 was performed. Data extraction included demographic data, surgical data, and outcome data, which pertinently examined surgical method, progression to therapeutic procedure, clinically significant adverse events, and Engel outcomes.Results: One hundred and fifty‐two sEEG procedures were performed on 131 patients. Procedures averaged 10.5 electrodes for a total of 1603 electrodes. The majority (84%) of patients progressed to a therapeutic procedure. Six clinically significant complications occurred: three retained electrodes, two hemorrhages, and one failure to complete investigation. Only one complication resulted in a permanent deficit. Engel 1 outcome was achieved in 63.3% of patients reaching one‐year follow‐up after a curative procedure.Significance: New or expanding epilepsy surgery centers can appropriately consider the use of sEEG. The complication rate is low and the majority of patients progress to therapeutic surgery. Procedural safety, progression to therapeutic intervention, and Engel outcomes are comparable to cohorts from long‐established epilepsy surgery programs.

1 September 2025 in JAMA Neurology
Verified
Journal Article
Open access
PLPatrick Landazuri
Patrick Landazuri
JCJennifer J. Cheng
Jennifer J. Cheng
ELEric Leuthardt
Eric Leuthardt
AKAlbert H. Kim
Albert H. Kim
DSDerek G. Southwell
Derek G. Southwell
JBJames Baumgartner
James Baumgartner
Importance: Laser interstitial thermal therapy (LITT) is a surgical tool used to ablate epileptic foci and brain tumors. Understanding clinical and procedural outcomes of LITT for mesial temporal lobe epilepsy (MTLE) is relevant to clinicians and patients.Objective: To describe seizure outcomes, procedural outcomes, and safety data of MTLE LITT.Design, Setting, and Participants: Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) is a prospective multicenter registry with up to 5 years of follow-up lasting from October 2015 to March 2023 at LAANTERN epilepsy sites, which are all level IV National Association of Epilepsy Centers in the US. Adult and pediatric LAANTERN enrollees undergoing LITT for drug-resistant MTLE with at least 6 months of follow-up were included. Those with epilepsy related to a malignant lesion were excluded.Intervention: LITT for drug-resistant MTLE.Main Outcomes and Measures: Demographic, epilepsy, and seizure characteristics; procedural data; postsurgical seizure outcomes; safety data; and quality of life (QOL) scores were prospectively collected.Results: Fifteen centers enrolled 145 patients (73 [50.3%] female) with MTLE undergoing LITT, with 77 reaching 2-year follow-up. The mean (SD) age was 39.2 (15.4) years at time of LITT with 14 of 145 in the pediatric range (younger than 22 years). The 2 most common etiologies were mesial temporal sclerosis (n = 74) and unknown etiology or magnetic resonance imaging normal (n = 31). Mean (SD) ablation volume was 28.2 (29.8) mL. Mean (SD) surgery duration was 4.3 (2.1) hours, and mean (SD) blood loss was 22 (17.6) mL. Median (IQR) length of stay was 1 (1-3) day, and 33 patients (23%) had no intensive care unit stay postprocedure. Median (IQR) intensive care unit time was 22 (19.2-28.8) hours. Mean (SD) discharge head pain score was 2.1 (2.6) on a 0-10 scale. Most patients (n = 140 [96.6%]) were discharged home. Two-year seizure outcomes were 45 of 77 (58.4%) and 44 of 77 (57.2%) for Engel 1 and International League Against Epilepsy 1/2, respectively. No clinical characteristics were associated with seizure outcome. Adverse events were seen in 24 patients (16.5%), most being mild and transient. Pediatric seizure outcomes were similar to adult outcomes. One-third of patients stopped or decreased their antiseizure medicines. Improvements in QOL scores were seen at almost all time points assessed.Conclusions: In the largest prospective multicenter MTLE LITT cohort, LITT was found to be well tolerated with clinically meaningful seizure outcomes and QOL improvements. These findings indicate that LITT may be considered as a treatment option for drug-resistant MTLE.

19 February 2020 in Epilepsia
Verified
Journal Article
Closed access
PDF file
APAndré Palmini
André Palmini
NANaoki Akamatsu
Naoki Akamatsu
TBThomas Bast
Thomas Bast
SBSebastian Bauer
Sebastian Bauer
CBChristoph Baumgartner
Christoph Baumgartner
PWPeter Widdess‐Walsh
Peter Widdess‐Walsh

3 June 2026 in Epilepsia
Verified
Journal Article
Open access
UUUtku Uysal
Utku Uysal
PLPatrick Landazuri
Patrick Landazuri
DBDavid E. Burdette
David E. Burdette
SPSanjay Patra
Sanjay Patra
ACAngela N. Crudele
Angela N. Crudele
MMMartha J. Morrell
Martha J. Morrell
Objective: This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods: NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial. Patients were ≥12 years of age with drug‐resistant IGE and ≥2 GTCSs over a 3‐month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open‐label active stimulation. The primary safety endpoint was the serious adverse device‐related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time‐to‐second‐GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). Results: Eighty‐seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed‐effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen‐month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS‐free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. Significance: NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much‐needed option for drug‐resistant IGE.

10 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GOGloria Ortiz-Guerrero
Gloria Ortiz-Guerrero
MLMaggie Logan
Maggie Logan
UUUtku Uysal
Utku Uysal
PLPatrick Landazuri
Patrick Landazuri
LJLakeshia Jackson
Lakeshia Jackson
CUCarol M. Ulloa
Carol M. Ulloa
Background: The potential for racial disparity using urine drug screening (UDS) in patients with seizures is sparsely reported. This study aims to determine racial and ethnic disparities when ordering UDS in patients with suspected seizures in the emergency department (ED). Methods: In this retrospective study, we identified patients over the age of 18 with suspected seizures who presented to the ED at the University of Kansas Medical Center between October 2017 and October 2020. Data encompassed demographic, clinical, electrographic, and UDS information from the electronic medical records (EMR). Data were compared between Black and White patients, as well as between Hispanic and non-Hispanic patients. We used the Chi-square test to assess differences in UDS testing based on patient race and ethnicity. Results: A total of 2945 patients were identified. Among these, 1750 (59%) were White and 821 (28%) were Black patients. Of these patients, 612 (20.8%) underwent UDS in the ED. Black patients had UDS performed more frequently compared to White patients (p = 0.046). Additionally, the positivity rate for UDS was higher among Black patients than White patients (p = 0.019). UDS testing did not differ by ethnicity (p = 0.164). Amphetamine positivity was higher among White patients; however, the positivity rates of other drugs did not differ by race and ethnicity. Black patients were more often admitted to the neurology intensive care unit. No differences in discharge rates or EEG testing were noted across race or ethnicity. Conclusion: Increased UDS testing was seen in Black patients compared to White patients in our single-institution cohort, warranting further research into the underlying causes of this disparity.